Ajanta Pharma's Q2 FY 2025-26 Quarterly Results

Result Summary

• Ajanta Pharma Ltd reported a 6.3% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 17.2%.
• Its expenses for the quarter were up by 7.5% QoQ and 17.1% YoY.
• The net profit increased 1.9% QoQ and increased 20.2% YoY.
• The earnings per share (EPS) of Ajanta Pharma Ltd stood at 20.82 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Ajanta Pharma Ltd is a well-established pharmaceutical company engaged in the development, manufacturing, and marketing of a diverse range of branded and generic pharmaceutical products. The company's product portfolio spans multiple therapeutic segments, including cardiology, dermatology, ophthalmology, and pain management, among others. Ajanta Pharma operates in various international markets, enhancing its global footprint. The company is recognized for its focus on research and development, which aids in launching innovative products that cater to unmet medical needs. Recent major developments, if any, are not available.

Revenue

In the second quarter of Fiscal Year 2026 (Q2FY26), Ajanta Pharma Ltd reported a total income of ₹1413.07 crores. This reflects a quarter-over-quarter (QoQ) increase of 6.3% from the previous quarter (Q1FY26), where the total income was ₹1328.98 crores. Year-over-year (YoY), the total income increased by 17.2% compared to ₹1206.12 crores in Q2FY25. These figures highlight the company's revenue growth over both the quarterly and annual periods under consideration.

Profitability

Ajanta Pharma Ltd's profitability metrics for Q2FY26 demonstrate an upward trend. The Profit Before Tax (PBT) for the quarter was ₹340.81 crores, marking a QoQ increase of 2.9% from ₹331.13 crores in Q1FY26 and a YoY increase of 17.4% compared to ₹290.24 crores in Q2FY25. The company's Profit After Tax (PAT) stood at ₹260.19 crores for Q2FY26, up by 1.9% QoQ from ₹255.34 crores in Q1FY26 and up by 20.2% YoY from ₹216.48 crores in Q2FY25. Additionally, the Earnings Per Share (EPS) for Q2FY26 was ₹20.82, representing a 1.9% increase QoQ and a 20.6% increase YoY.

Operating Metrics

In examining Ajanta Pharma Ltd's operating metrics for Q2FY26, total expenses were reported at ₹1072.26 crores, which signifies a 7.5% QoQ increase from ₹997.85 crores in Q1FY26 and a 17.1% YoY increase from ₹915.88 crores in Q2FY25. The tax expense for the quarter amounted to ₹80.62 crores, an increase of 6.4% QoQ from ₹75.79 crores in Q1FY26 and a 9.3% increase YoY from ₹73.76 crores in Q2FY25. These metrics indicate changes in operational costs and tax liabilities over the analyzed periods.